Looking at the pipeline of SPL product, crossing vivagel out,...

Looking at the pipeline of SPL product, crossing vivagel out, anything that follows is 5 years+ away. I can understand why it is declining, fund manager needs to report their performance half yearly or internal review quarterly and there are no points for them to sitting on a pile of SPL shares that will not likely go anywhere within a year.
As a holder I am just positioning myself ahead of everyone else, unless the data was made up, potential of DEP is huge. Risk: Reward ratio is favorable as the market is big. The longer the average lifespan of the population, the more demand for cancer drug.